Robert Orlowski, Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared a post on X:
“Myeloma Paper of the Day: Real-world experience of efficacy and safety of belantamab mafodotin in relapsed/refractory myeloma finds ORR and CR rates of 40.0 and 15.0%, median PFS and OS of 5 and 12 months.
However, this was all monotherapy and not with combos.”
Authors: Rachel Dileo, Prerna Mewawalla, Kalaivani Babu, Yue Yin, Christopher Strouse, Aliya Rashid, Bidushi Pokhrel, Nausheen Ahmed, Al-Ola Abdallah, Hamza Hashmi et al.
More posts featuring Robert Orlowski.
